Medication Safety in Patients with Liver Disease
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 6782
Special Issue Editors
Interests: medication safety; clinical decision support; cirrhosis; clinical pharmacology
Special Issue Information
Dear Colleagues,
The burden of chronic liver disease is rising, and clinicians face the challenge of safely managing medicines in this increasingly multimorbid patient group. Globally, the most prevalent chronic liver diseases are alcohol-associated liver disorder, nonalcoholic fatty liver disease, and viral hepatitis B and C. While treatment differs in the early stages, these chronic liver diseases all share a similar hepatitis-fibrosis sequence to cirrhosis.
Medication safety in liver disease is complex. Although medication errors can occur at any stage, people with advanced hepatic fibrosis and portal hypertension may be at greatest risk harm. Alterations in the pharmacology of medicines commonly occur in people with cirrhosis. Increased exposure to specific medications and the presence of complications (e.g., ascites, hepatic encephalopathy) can increase susceptibility to adverse effects. Patient behaviours (e.g. nonadherence) and health system factors (e.g. prescriber knowledge and support) may further complicate medication safety by reducing efficacy and impacting accessibility to pharmacotherapy and appropriate monitoring.
Tailored pharmacotherapy is needed to ensure safe and appropriate use of medicines in patients with liver disease. Pharmaceuticals invites all clinicians and researchers to share original contributions, reviews, and best practices that contribute to knowledge about medication safety in chronic liver disease. Topics may include pharmacological reviews, epidemiological studies, case reports of toxicological effects in patients with liver disease, and investigation of clinical interventions such as medication reviews to improve medication safety.
The collection of publications will be published as a Special Issue of the journal.
Dr. Sander D. BorgsteedeDr. Kelly L. Hayward
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Liver disease
- Medication safety
- Pharmacodynamics
- Pharmacokinetics
- Dosing
- Systematic review
- Case reports
- Epidemiology
- Implementation research
- Adverse drug reactions
- Clinical decision support
- Gastro-enterology
- Hepatology
- Clinical pharmacology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.